Setmelanotide

01 · What it is

Setmelanotide is what happens when a melanocortin agonist is aimed at people whose melanocortin pathway is genetically broken.

It is a melanocortin-4 receptor agonist ³, approved for severe obesity caused by deficiency of proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or the leptin receptor ⁸. The logic is unusually clean: POMC-derived peptides act on MC4R-expressing neurons to reduce body weight ¹, so in people whose own POMC signal is absent, supplying an agonist downstream of the lesion should restore it.

The pivotal evidence is strong in design terms and modest in effect terms. The registrational trials in POMC and LEPR deficiency were single-arm, open-label, multicentre phase 3 studies — no placebo group ². The randomised, double-blind, placebo-controlled phase 3 trial was in Bardet-Biedl and Alström syndromes, and its result is worth stating exactly: 32.3% of patients aged 12 or older with Bardet-Biedl syndrome reached at least a 10% reduction in bodyweight after 52 weeks, 95% CI 16.7 to 51.4, p = 0.0006 ⁴.

A third of patients hitting a 10% threshold, with a confidence interval running from 17% to 51%. That is a real effect in a population with no other pharmacological option, and it is not a large one.

The programme has kept going, and kept being tested. A phase 2 trial in acquired hypothalamic obesity ¹², a phase 3 trial in children aged 2 to 5 with rare MC4R-pathway obesity ¹⁵, and a phase 3 randomised trial in acquired hypothalamic obesity published in the New England Journal of Medicine in 2026 ²⁰. NICE appraised it for Bardet-Biedl syndrome in 2024 ¹¹.

This is the third approved melanocortin peptide in this family, and the comparison is the point. Afamelanotide was developed for a rare photosensitivity disorder and works. Setmelanotide was developed for rare genetic obesity syndromes and works, modestly. PT-141 was approved on outcomes that independent re-analysts dispute. Melanotan II was never developed at all and is known mainly through case reports of harm. Same receptor family, four completely different evidentiary situations.

02 · Evidence at a glance

Evidence grade

Approved Pharma — first approval documented in the peer-reviewed literature ³

Drug class

Melanocortin-4 receptor (MC4R) agonist ^3,8

Approved for

Severe obesity due to POMC, PCSK1 or LEPR deficiency ⁸; obesity in Bardet-Biedl syndrome ¹⁰

Rationale

POMC-derived peptides act on MC4R neurons to reduce body weight; the drug supplies an agonist downstream of the genetic lesion ¹

Registrational trials, POMC/LEPR

Single-arm, open-label, multicentre phase 3 — no placebo control ²

Randomised placebo-controlled evidence

Bardet-Biedl and Alström syndromes, phase 3 ⁴

Its headline result

32.3% of Bardet-Biedl patients aged ≥12 reached ≥10% bodyweight reduction at 52 weeks (95% CI 16.7–51.4; p = 0.0006) ⁴

First human data

28-day phase 1b in MC4R variant carriers ¹

Paediatric extension

Phase 3 in ages 2–5 with rare MC4R-pathway obesity (VENTURE) ¹⁵

Acquired hypothalamic obesity

Phase 2 ¹², then a phase 3 randomised trial in NEJM 2026 (TRANSCEND) ²⁰

Health-technology assessment

NICE, 2024, for Bardet-Biedl syndrome ¹¹

Prader-Willi syndrome

No approved therapeutic exists; trials reviewed separately ⁵

Craniopharyngioma-related obesity

Reviewed; no pharmaceutical cure available ¹⁸

03 · Mechanism of action

An agonist placed downstream of the defect

Proopiomelanocortin-derived peptides act on neurons expressing the melanocortin-4 receptor to reduce body weight ¹. Severe early-onset obesity can be caused by biallelic variants in genes affecting that pathway ² — POMC itself, PCSK1 which processes it, or the leptin receptor upstream of it.

Setmelanotide binds MC4R directly. In each of these conditions the receptor is intact while the signal reaching it is not, which is why an agonist works and why the indication is defined genetically rather than by body mass index.

This is the most mechanistically coherent drug in the project. The lesion is known, the target is known, the drug sits between them, and the indication is written in terms of the lesion.

Why the same drug helps in Bardet-Biedl syndrome

Bardet-Biedl syndrome is a ciliopathy with pleiotropic manifestations observable in utero and progressing with age ¹⁴, in which early-onset obesity and hyperphagia are prominent and contribute substantially to clinical morbidity and caregiver burden ⁹. MC4R signalling depends on ciliary function, which is the connection that made the trial reasonable.

Hyperphagia is the symptom that matters here. Weight is the measured endpoint; the drive to eat is what families describe as the problem.

And why it is being tried in acquired hypothalamic obesity

Hypothalamic obesity arises when the brain circuitry regulating energy balance is damaged rather than genetically altered — most often after treatment for childhood craniopharyngioma ¹⁸, and it is reviewed as a condition in its own right ^10,16. There is compelling genetic, clinical and experimental evidence for the contribution of brain circuits to obesity generally ¹⁶, and setmelanotide has been investigated on the reasoning that an MC4R agonist may compensate for disrupted upstream signalling regardless of whether the disruption is inherited or acquired ^12,20.

Extending from a genetic lesion to an acquired injury in the same pathway is a real hypothesis, and it was tested in a phase 2 and then a randomised phase 3 rather than assumed ^12,20.

04 · Key research findings

First human data, 2017. A 28-day phase 1b trial in obese carriers of MC4R variants, reporting weight loss and establishing the pharmacological premise ¹.

The registrational trials, 2020. Single-arm, open-label, multicentre phase 3 trials in individuals with severe obesity due to POMC or LEPR deficiency ².

Single-arm and open-label. In an ultra-rare genetic disorder a placebo arm is difficult to justify and difficult to recruit, and that constraint is real — but it means the strongest efficacy claims in these two indications rest on uncontrolled data, and a reader should know that.

First approval, 2021. A review documenting the approval and noting that development was continuing in other rare genetic obesity disorders including Bardet-Biedl syndrome, Alström syndrome, POMC and other MC4R-pathway heterozygous deficiency obesities, and POMC epigenetic disorders ³.

The randomised trial, 2022. A multicentre, randomised, double-blind, placebo-controlled phase 3 trial with an open-label period, in Bardet-Biedl and Alström syndromes. On the primary endpoint, 32.3% of patients aged 12 or older with Bardet-Biedl syndrome achieved at least a 10% reduction in bodyweight after 52 weeks, 95% CI 16.7 to 51.4, p = 0.0006 ⁴.

This is the one placebo-controlled pivotal trial in the file, and its number is the number to quote for this drug. Roughly one patient in three crossing a 10% threshold, in a syndrome with no alternative.

Clinical positioning, 2023–2024. Reviews of current treatments for genetic obesity ⁷; of obesity pharmacotherapy generally ^6,13; of paediatric obesity pharmacology ¹⁷; a StatPearls entry setting out the approved genetic indications ⁸; a clinical overview of Bardet-Biedl syndrome noting that setmelanotide is a new pharmacotherapy approved for obesity in BBS ¹⁰; and an inter-European Reference Networks consensus statement revising BBS diagnostic criteria ¹⁴.

Consensus statements and diagnostic-criteria revisions are what happens around a drug once it exists: the diagnostic infrastructure has to catch up to identify who should receive it.

Acquired hypothalamic obesity, 2024 and 2026. A phase 2, open-label, multicentre trial across five US centres, with a long-term extension ¹²; and TRANSCEND, a phase 3 randomised trial published in the New England Journal of Medicine in July 2026 ²⁰.

A phase 2 signal taken into a randomised phase 3 and published in a top-tier journal is orthodox drug development, and it is the most recent evidence in this guide.

Paediatric extension, 2025. VENTURE, a one-year, open-label, multicentre phase 3 trial in patients aged 2 to 5 years with rare MC4R-pathway-associated obesity, in a drug previously shown to reduce hunger and weight in patients aged 6 and older with POMC deficiency ¹⁵.

Deliberate age extension with a dedicated trial, rather than extrapolation. Note the endpoint language: hunger as well as weight.

The boundaries of the indication, 2023–2025. No approved therapeutic exists for Prader-Willi syndrome, where control of hyperphagia remains the most important unmet need ⁵. In acquired hypothalamic obesity after childhood-onset craniopharyngioma, despite promising approaches including central stimulants, antidiabetic drugs, GLP-1 receptor agonists and setmelanotide, no pharmaceutical cure is available ¹⁸. Reviews of obesity pharmacotherapy place setmelanotide among FDA-approved agents while the field’s centre of gravity moves to incretins ¹⁹.

These are the honest edges. The drug is approved for specific genetic diagnoses, not for obesity, and the reviews covering adjacent conditions say plainly that the problem there remains unsolved.

05 · Evidence overview

06 · Safety profile

Human data, from a regulated development programme. Safety was assessed in the phase 1b study ¹, in the single-arm phase 3 trials in POMC and LEPR deficiency ², in the randomised placebo-controlled trial in Bardet-Biedl and Alström syndromes with its open-label period ⁴, in a dedicated paediatric trial down to age 2 ¹⁵, and in phase 2 and phase 3 trials in acquired hypothalamic obesity including a long-term extension ^12,20. NICE examined it ¹¹.

This guide has read abstracts rather than full texts and therefore does not enumerate specific adverse events, rates or warnings. Those belong to the label and to the full trial reports. What can be said is structural: this compound has been through the process that generates a safety dataset, in multiple populations including very young children, with regulatory and health-technology review — and that is the difference between it and most of what this project covers.

What is genuinely unknown, or outside the studied population. Everything about use outside the approved genetic diagnoses. Every trial cited here enrolled patients with a defined genetic or acquired hypothalamic lesion ^{1,2,4,12,15,20}. Nothing here establishes what an MC4R agonist does in someone with common obesity and an intact melanocortin pathway, which is the population most likely to encounter the compound informally.

Two specific gaps. Pigmentation — MC4R selectivity is the design intent, and this guide located no source characterising cross-reactivity at MC1R or long-term dermatological monitoring; the melanocortin family’s shared pharmacology makes that a reasonable question rather than an idle one. And long-term outcomes beyond the trial horizons, in conditions that are lifelong.

Nothing is published on the identity or purity of any material sold under this name outside a pharmacy supply chain.

07 · US regulatory status

Current as of 7 September 2026. Setmelanotide is an approved prescription medicine. Its first approval is documented in the peer-reviewed literature ³, and it is described as approved for severe obesity caused by POMC, PCSK1 or LEPR deficiency ⁸ and for obesity in Bardet-Biedl syndrome ¹⁰. NICE appraised it for Bardet-Biedl syndrome in 2024 ¹¹. It is not a controlled substance.

This guide has not consulted the FDA or EMA approval records, labels or review documents, and states approval status on the authority of the peer-reviewed sources cited. Indication wording, age restrictions, contraindications and warnings are matters for the label and are not reproduced or paraphrased here.

Under the World Anti-Doping Code, setmelanotide does not appear as a named prohibited substance in the classes reviewed for this guide. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The registrational trials in the original indications had no control group. Single-arm, open-label phase 3 ². This is a defensible design choice in ultra-rare disease and it still means the POMC and LEPR efficacy claims are uncontrolled.
2. The one placebo-controlled result is moderate. 32.3% reaching a 10% weight-loss threshold at 52 weeks, with a confidence interval from 16.7% to 51.4% ⁴. Roughly two-thirds of patients did not reach that threshold.
3. The approved population is defined genetically, and is very small. POMC, PCSK1 and LEPR deficiency and Bardet-Biedl syndrome ^8,10. Nothing in this file supports use in common obesity, and the mechanism gives positive reason to expect less benefit where the pathway is intact.
4. Extension to acquired hypothalamic obesity is recent. Phase 2 in 2024 ¹² and phase 3 in 2026 ²⁰; this guide has read the phase 3 only as an abstract and does not report its result.
5. Weight is the endpoint; hyperphagia is the burden. Reviews describe hyperphagia and its effect on caregivers as the dominant clinical problem ^5,10, and trial endpoints in this file are predominantly weight-based, with hunger mentioned ¹⁵ but not quantified in what was read.
6. Sponsor involvement runs through the trial literature, as is normal for a rare-disease programme, with recurring investigator groups across the phase 3 studies ^2,4,15,20. Independent replication outside the development programme is not evident in this file.
7. No long-term data beyond trial horizons in lifelong conditions.
8. Receptor selectivity is stated by the sources as MC4R agonism ^3,8 and this guide located no binding study characterising activity at other melanocortin receptors.
9. This guide has read abstracts, not full texts, for every source cited, and consequently reports no adverse-event data.
10. No regulatory record was consulted.
11. Nothing is known about material sold under this name outside a pharmacy.

09 · References

1. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O’Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency. Mol Metab. 2017 Oct;6(10):1321–1329.

   PMID 29031731 ↗

2. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960–970.

   PMID 33137293 ↗

3. Markham A. Setmelanotide: first approval. Drugs. 2021 Feb;81(3):397–403. Review.

   PMID 33638809 ↗

4. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022 Dec;10(12):859–868.

   PMID 36356613 ↗

5. Mahmoud R, Kimonis V, Butler MG. Clinical trials in Prader-Willi syndrome: a review. Int J Mol Sci. 2023 Jan 21;24(3):2150. Review.

   PMID 36768472 ↗

6. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023 Mar 20;58:101882. Review.

   PMID 36992862 ↗

7. Faccioli N, Poitou C, Clément K, Dubern B. Current treatments for patients with genetic obesity. J Clin Res Pediatr Endocrinol. 2023 May 29;15(2):108–119. Review.

   PMID 37191347 ↗

8. Hussain A, Farzam K. Setmelanotide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jul 2.

   PMID 36943959 ↗

9. Shoemaker A. Bardet-Biedl syndrome: a clinical overview focusing on diagnosis, outcomes and best-practice management. Diabetes Obes Metab. 2024 Apr;26 Suppl 2:25–33. Review.

   PMID 38383825 ↗

10. Roth CL, McCormack SE. Acquired hypothalamic obesity: a clinical overview and update. Diabetes Obes Metab. 2024 Apr;26 Suppl 2:34–45.

    PMID 38450938 ↗

11. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome. London: National Institute for Health and Care Excellence (NICE). 2024 May 22. No abstract available..

    PMID 40203162 ↗

12. Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Abuzzahab MJ. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024 Jun;12(6):380–389.

    PMID 38697184 ↗

13. Yanovski SZ, Yanovski JA. Approach to obesity treatment in primary care: a review. JAMA Intern Med. 2024 Jul 1;184(7):818–829. Review.

    PMID 38466272 ↗

14. Dollfus H, Lilien MR, Maffei P, Verloes A, Muller J, Bacci GM, Cetiner M, van den Akker ELT, Grudzinska Pechhacker M, Testa F, Lacombe D, Stokman MF, Simonelli F, Gouronc A, Gavard A, van Haelst MM, Koenig J, Rossignol S, Bergmann C, Zacchia M, Leroy BP, Mosbah H, Van Eerde AM, Mekahli D, Servais A, Poitou C, Valverde D. Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations. Eur J Hum Genet. 2024 Nov;32(11):1347–1360. Review.

    PMID 39085583 ↗

15. Argente J, Verge CF, Okorie U, Fennoy I, Kelsey MM, Cokkinias C, Scimia C, Lee HM, Farooqi IS. Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Jan;13(1):29–37.

    PMID 39549719 ↗

16. Argente J, Farooqi IS, Chowen JA, Kühnen P, López M, Morselli E, Gan HW, Spoudeas HA, Wabitsch M, Tena-Sempere M. Hypothalamic obesity: from basic mechanisms to clinical perspectives. Lancet Diabetes Endocrinol. 2025 Jan;13(1):57–68. Review.

    PMID 39547253 ↗

17. Fox CK, Kelly AS, Reilly JL, Theis-Mahon N, Raatz SJ. Current and future state of pharmacological management of pediatric obesity. Int J Obes (Lond). 2025 Mar;49(3):388–396. Review.

    PMID 38321079 ↗

18. Müller HL. Management of acquired hypothalamic obesity after childhood-onset craniopharyngioma — a narrative review. Biomedicines. 2025 Apr 22;13(5):1016. Review.

    PMID 40426846 ↗

19. Fredrick TW, Camilleri M, Acosta A. Pharmacotherapy for obesity: recent updates. Clin Pharmacol. 2025 Sep 19;17:305–327. Review.

    PMID 40995421 ↗

20. Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL; TRANSCEND Trial Group. Setmelanotide for the treatment of acquired hypothalamic obesity. N Engl J Med. 2026 Jul 9;395(2):138–150.

    PMID 42418774 ↗